{"id":"adx-2191","safety":{"commonSideEffects":[{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Increased intraocular pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting ROCK, ADX-2191 aims to reduce inflammation and prevent abnormal cell growth, which can be beneficial in treating certain ocular conditions such as proliferative vitreoretinopathy (PVR).","oneSentence":"ADX-2191 is designed to inhibit the activity of Rho-associated protein kinase (ROCK), which is involved in various cellular processes including inflammation and cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:07.352Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Proliferative vitreoretinopathy (PVR)"}]},"trialDetails":[{"nctId":"NCT07402876","phase":"PHASE3","title":"A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma","status":"RECRUITING","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2026-02","conditions":"Primary Vitreoretinal Lymphoma","enrollment":20},{"nctId":"NCT04136366","phase":"PHASE3","title":"The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-11-15","conditions":"Proliferative Vitreoretinopathy","enrollment":106},{"nctId":"NCT05392179","phase":"PHASE2","title":"A Study in Subjects With Retinitis Pigmentosa","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2022-07-14","conditions":"Retinitis Pigmentosa","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ADX-2191","genericName":"ADX-2191","companyName":"Aldeyra Therapeutics, Inc.","companyId":"aldeyra-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ADX-2191 is designed to inhibit the activity of Rho-associated protein kinase (ROCK), which is involved in various cellular processes including inflammation and cell proliferation. Used for Proliferative vitreoretinopathy (PVR).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}